AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01618032 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Manual contact during a period of time similar of teh other interventions
Study NCT01324817 — intervention group
Intervention type: DEVICE
Intervention: Kai Spot (v 2.1)
Description: The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
Study NCT01324817 — intervention group
Intervention type: DEVICE
Intervention: Kai Continuous (v 1.0)
Description: The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
Study NCT02760966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol 70º
Study NCT02760966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soap
Study NCT04215926 — intervention group
Intervention type: OTHER
Intervention: No intervention; cross-sectional study
Description: No intervention; cross-sectional study
Study NCT04122326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workstation Modification
Description: Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
Study NCT04013607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructo- and galacto-oligosaccharides
Description: A NDC drink rich in fructo- and galacto-oligosaccharides
Study NCT05283551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir (500mg BD)
Study NCT00677404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MNC injection
Description: Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
Study NCT03484273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWrap Compression Garment
Description: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
Study NCT04033367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT04033367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT04033367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT01960140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01960140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally
Study NCT01759043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding catheter
Description: using a single transradial guiding catheter for coronary angiography and intervention
Study NCT01759043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic catheter
Description: diagnostic for coronary angiography and guiding catheter selection for intervention
Study NCT01020786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity.
Study NCT01020786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
Study NCT02939365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
Study NCT04280302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Rehabilitation
Description: VR-based eye stabilization exercises and balance exercises
Study NCT04280302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
Study NCT01288521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Ketoconazole, Then Tacrolimus alone
Description: Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
Study NCT01288521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus alone, Then Tacrolimus + Ketoconazole
Description: Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
Study NCT01460108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal System
Description: 20 mL
Study NCT01018030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg QD
Description: Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
Study NCT01018030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg BID
Description: Active Nasal Spray (AM) and Active Nasal Spray (PM)
Study NCT01018030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
Study NCT01536717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine hydrochloride 2% solution
Description: * 4 ml/h periosteal wound infusion~* duration of 72 h
Study NCT02412410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue avoidance education
Description: Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
Study NCT00195091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime.
Study NCT02611791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
Study NCT02611791 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency - OFF
Description: The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
Study NCT01536717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo Sodium chloride 0,9%
Study NCT04579146 — intervention group
Intervention type: OTHER
Intervention: coronary computed tomographic angiographic (CCTA)
Description: x-ray examination with contrast by a 64-slice CT coronary angiography.
Study NCT01582061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide sub-cutaneous
Description: Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
Study NCT01255423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium topical gel 1%
Description: Diclofenac sodium topical gel 1%, 4 times daily
Study NCT01255423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 times daily
Study NCT04072913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal samples (biopsies + vaginal smear)
Description: Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
Study NCT03567772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wiifit Nintendo video game
Study NCT03567772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation program
Study NCT03567772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Study NCT03498950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: laser irradiation on the taste papillae
Study NCT01404507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gp 2b 3a inhibitor
Description: bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
Study NCT01404507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aspiration thrombectomy
Description: Aspiration thrombectomy via aspiration catheter
Study NCT01404507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Both use
Description: Both use of intracoronary abciximab and aspiration thrombectomy
Study NCT00815217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of lipoaspirate
Description: Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
Study NCT00815217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
Study NCT04591938 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fantom Encore Bioresorbable scaffold implantation
Description: Fantom Encore Bioresorbable scaffold implantation
Study NCT03211468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention program to prevent eating disorders
Description: See previous
Study NCT02218684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02218684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine
Study NCT02218684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00702468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
Study NCT00702468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
Study NCT01994642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
Study NCT01994642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
Study NCT01994642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sterile Otic Suspension
Study NCT03512834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
Study NCT03512834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
Study NCT01701206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV knowledge Intervention
Study NCT01612975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
Study NCT01612975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
Study NCT04598022 — intervention group
Intervention type: OTHER
Intervention: cross-sectional observation
Description: observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester
Study NCT04598022 — intervention group
Intervention type: OTHER
Intervention: cross-sectional follow-up observation
Description: follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
Study NCT00160186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin
Description: 2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
Study NCT03070249 — intervention group
Intervention type: BEHAVIORAL
Intervention: Professional Quality of Life (ProQoL) scale
Description: COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
Study NCT02210403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study NCT00160186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00232622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Description: Accelerated infusion of streptokinase
Study NCT00232622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: Standard dose streptokinase
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein whole foods
Description: Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein whole foods
Description: Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Resistance Exercise Training
Description: Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Resistance Exercise Training
Description: Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Stretching/Yoga Training
Description: Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
Study NCT02190136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Stretching/Yoga Training
Description: Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
Study NCT05089006 — intervention group
Intervention type: PROCEDURE
Intervention: Partial nephrectomy with robot-assisted and open surgery
Description: Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
Study NCT04138303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
Study NCT04138303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-Restrictive Low Carbohydrate Diet (CR-LC)
Description: Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
Study NCT04138303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancestral Diet (AD)
Description: Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
Study NCT02210403 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study NCT02258256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphygmo
Description: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Study NCT02557607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
Study NCT01834053 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous Stem Cell
Description: Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'